NordicRWE: Unleashing the power of Nordic health data to bring life-changing therapies to patients faster

The landscape of drug development is evolving rapidly, driven by innovations in new personalised medicine and biomarker-driven therapies for smaller and more specific patient groups.

These advancements bring unique challenges, including faster drug development timelines, shorter follow-up periods, intermediary endpoints and conditional approvals.

These pressures make it increasingly difficult to balance the efficacy, safety and cost-effectiveness of new therapies.

Addressing these challenges requires innovative evidence-generation strategies.

Data-driven drug development, powered by real-world data (RWD), is becoming a vital part of this transformation. Insights derived from health data are now integral across the entire healthcare value chain, influencing drug development, regulatory processes and post-market surveillance. This underscores the importance of robust solutions for accessing, analysing and interpreting real-world evidence (RWE).

The Nordic countries offer a unique advantage with their universal, publicly funded healthcare systems that collect comprehensive lifelong RWD on all residents. This “cradle-to-grave” data provides an unparalleled source of high-quality longitudinal data, ideal for life science research.

NordicRWE specialises in delivering solutions and services that harness the power of Nordic health data for transformative drug development.

Current focus areas include several groundbreaking applications of RWE:

Using RWD to compare new treatments with existing ones, replicate randomised controlled trial (RCT) results, and construct external control arms for single-arm trials.

Combining hypothesis-free analytical approaches with pharmacoepidemiological hypothesis validation to support drug discovery and enhance drug surveillance.

Exploring the integration of generative AI and advanced language models on health data for various applications in drug development.

NordicRWE transforms complex RWD into meaningful insights that drive more efficient drug development and better healthcare outcomes.

Key benefits include:

Ensuring reliability in research findings.

Utilising RWE insights to reduce uncertainty in decision-making.

Enabling faster and more efficient development of therapies to benefit patients sooner.

By unlocking the full potential of Nordic health data, NordicRWE aims to set a new global standard for RWE generation.

The company’s scalable solutions cater to a wide spectrum of clients, from global pharmaceutical leaders to emerging biotech firms and healthcare providers. NordicRWE is committed to driving innovation in drug development while delivering measurable improvements in healthcare outcomes.